Pliant Therapeutics Financial Results
Pliant Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting strong enrollment in its Phase 1b FORTIFY trial for PLN-101095. The company ended the quarter with $388.5 million in cash and equivalents, providing a projected cash runway into 2027. Key operational milestones included preclinical data for its integrin-mediated drug delivery platform and leadership appointments in medical and research roles.
- Term
- Q3 2026
“The third quarter reflected continued strong execution across the Organization, including robust FORTIFY enrollment and compelling proof-of-concept data generated from our integrin-mediated drug delivery platform.”
Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant